- Home
- BIO vs CHE Comparison
BIO vs CHE Comparison
Compare BIO & CHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIO
- CHE
- Stock Information
- Founded
- BIO 1952
- CHE 1970
- Country
- BIO United States
- CHE United States
- Employees
- BIO N/A
- CHE N/A
- Industry
- BIO Biotechnology: Laboratory Analytical Instruments
- CHE Medical/Nursing Services
- Sector
- BIO Industrials
- CHE Health Care
- Exchange
- BIO Nasdaq
- CHE Nasdaq
- Market Cap
- BIO 8.7B
- CHE 8.7B
- IPO Year
- BIO N/A
- CHE N/A
- Fundamental
- Price
- BIO $334.14
- CHE $580.52
- Analyst Decision
- BIO Buy
- CHE Buy
- Analyst Count
- BIO 4
- CHE 2
- Target Price
- BIO $369.00
- CHE $673.50
- AVG Volume (30 Days)
- BIO 209.2K
- CHE 53.1K
- Earning Date
- BIO 10-24-2024
- CHE 10-29-2024
- Dividend Yield
- BIO N/A
- CHE 0.35%
- EPS Growth
- BIO N/A
- CHE 31.50
- EPS
- BIO N/A
- CHE 19.72
- Revenue
- BIO $2,562,604,000.00
- CHE $2,335,557,000.00
- Revenue This Year
- BIO N/A
- CHE $8.90
- Revenue Next Year
- BIO $4.49
- CHE $7.70
- P/E Ratio
- BIO N/A
- CHE $29.27
- Revenue Growth
- BIO N/A
- CHE 6.79
- 52 Week Low
- BIO $261.59
- CHE $497.37
- 52 Week High
- BIO $377.88
- CHE $654.62
- Technical
- Relative Strength Index (RSI)
- BIO 56.82
- CHE 57.67
- Support Level
- BIO $311.04
- CHE $558.41
- Resistance Level
- BIO $333.60
- CHE $576.28
- Average True Range (ATR)
- BIO 8.26
- CHE 8.02
- MACD
- BIO -0.36
- CHE -0.45
- Stochastic Oscillator
- BIO 73.95
- CHE 73.66
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
About CHE Chemed Corp
Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.